Evidence Snapshot

3-hydroxy-3-methylglutaryl-coenzyme A reductase

CHEMBL402 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:03Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:20 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL402

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 3-hydroxy-3-methylglutaryl-coenzyme A reductase as ChEMBL target CHEMBL402, mapped to UniProt P04035. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

3-hydroxy-3-methylglutaryl-coenzyme A reductase

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL402

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P04035

3-hydroxy-3-methylglutaryl-coenzyme A reductase

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 3-hydroxy-3-methylglutaryl-coenzyme A reductase matters

As of 2026-09-13

3-hydroxy-3-methylglutaryl-coenzyme A reductase is reviewed as 3-hydroxy-3-methylglutaryl-coenzyme A reductase (UniProt P04035); 3-hydroxy-3-methylglutaryl-coenzyme A reductase shows approved-linked disease relevance led by Hypercholesterolemia. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 16 approved drugs, 1334 compounds, and 138 assays, with lead potency reaching pChEMBL 10.8.

Protein context

3-hydroxy-3-methylglutaryl-coenzyme A reductase

3-hydroxy-3-methylglutaryl-coenzyme A reductase Sequence length is 888 aa.

Review this target as 3-hydroxy-3-methylglutaryl-coenzyme A reductase, mapped to UniProt P04035. Sequence length is 888 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P04035 Protein

Disease context

Hypercholesterolemia

3-hydroxy-3-methylglutaryl-coenzyme A reductase shows approved-linked disease relevance led by Hypercholesterolemia. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ATORVASTATIN CALCIUM, FLUVASTATIN SODIUM, LOVASTATIN.

Start review with Hypercholesterolemia because it currently carries approved-linked support. Linked drugs include ATORVASTATIN CALCIUM, FLUVASTATIN SODIUM, LOVASTATIN, PITAVASTATIN CALCIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 8 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 1334 compounds, and 138 assays for this target. The dominant activity type is IC50. CHEMBL162642 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL162642 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine

16 approved pChEMBL 10.8

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 3-hydroxy-3-methylglutaryl-coenzyme A reductase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04035, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Hypercholesterolemia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1334

Total Compounds

138

Total Assays

Approved Drugs

IC50: 1149.0, KI: 846.0, EC50: 48.0, KD: 26.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL162642	10.8	IC50	—
No preferred name CHEMBL159951	10.7	IC50	—
No preferred name CHEMBL160102	10.3	IC50	—
No preferred name CHEMBL1477	10.1	IC50	Approved
No preferred name CHEMBL2375155	10.0	IC50	—

Approved Drugs

Structure	Compound	First Approval
	ROSUVASTATIN CHEMBL1496	2003
	CERIVASTATIN CHEMBL1477	1997
	ATORVASTATIN CHEMBL1487	1996
	FLUVASTATIN CHEMBL2220442	1993
	SIMVASTATIN CHEMBL1064	1991
	PRAVASTATIN CHEMBL1144	1991
	PRAVASTATIN SODIUM CHEMBL690	1991
	LOVASTATIN CHEMBL503	1987

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:03Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:20 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL402